Table 3. The incidence of adverse symptomatic radiation effect.

	Total 81, n (%)	Microhemorrhage +, n (%)	Microhemorrhge–, n (%)	p-value a	Time interval b
Headache	43 (53.1)	30 (50)	13 (61.9)	0.448	15 (3–129)
Dizziness or vertigo	20 (24.7)	12 (20)	8 (38.1)	0.140	16.5 (3–78)
Sleepiness	12 (14.8)	10 (16.7)	2 (9.5)	0.722	30 (3–78)
Skin problem	13 (16.0)	8 (13.3)	5 (23.8)	0.305	15 (3–51)
Cognitive dysfunction	24 (26.9)	20 (33.3)	4 (19.0)	0.274	25.5 (6–129)
Newly developed Seizure	9/63 c (14.3)	8/47 c (21.3)	1/16 c (6.3)	0.434	48 (9–108)
Language dysfunction	5 (6.2)	5 (8.3)	0 (0)	0.320	15 (3–144)
Motor weakness	13 (16.0)	9 (15.0)	4 (19.0)	0.733	30 (9–90)
Sensory change	3 (3.7)	2 (3.3)	1 (4.8)	1.000	36 (30–51)
Blurred vision	8 (9.9)	8 (13.3)	0 (0)	0.104	24 (6–114)

^a Statistical significance of the difference in the incidence of each symptom between the patients with an intracerebral hemorrhage and without an intracerebral hemorrhage

^b Time interval from radiation therapy to symptom onset, median months (range)

^c Eighteen patients who experienced seizure before radiation therapy were excluded from this analysis.